TNF and Blau syndrome: The drug should be selected according to the knowledge or established guidelines for every systemic disease (e.g., the preferred medication for panuveitis in patients with Blau syndrome is based on TNF blockers, as they are the agents indicated for the systemic and ocular manifestations of Blau syndrome) (5).